Related Experiment Video

Updated: Apr 20, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.7K

Resistance to targeted cancer drugs through hepatocyte growth factor signaling

Guus J J E Heynen1, Aldona Fonfara, René Bernards

  • 1a Division of Molecular Carcinogenesis and Cancer Genomics Netherlands ; The Netherlands Cancer Institute ; Amsterdam , The Netherlands.

Cell Cycle (Georgetown, Tex.)
|November 27, 2014
PubMed

Insights

Targeted cancer therapies show initial promise, but drug resistance is common. Hepatocyte Growth Factor (HGF) and its receptor MET signaling play a significant role in enabling cancer cells to resist these treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Targeted cancer therapies offer initial efficacy but frequently encounter inevitable drug resistance.
  • Cancer cells develop diverse mechanisms to evade the effects of targeted drugs.
  • Hepatocyte Growth Factor (HGF) and its receptor MET are implicated in various cellular processes, including cancer progression.

Purpose of the Study:

  • To review and present data on the role of HGF/MET signaling in acquired resistance to targeted cancer therapies.
  • To investigate the potential of HGF to confer resistance to kinase inhibitors across different cancer cell lines.

Main Methods:

  • Literature review of HGF/MET signaling in drug resistance.
  • Experimental data demonstrating HGF-induced resistance to kinase inhibitors in cancer cell lines.

Main Results:

  • HGF was shown to confer resistance to multiple kinase inhibitors.
  • This resistance was observed across a variety of cancer cell lines.
  • The findings support a significant role for HGF/MET signaling in mediating resistance.

Conclusions:

  • HGF/MET signaling is a critical factor in the development of resistance to targeted cancer drugs.
  • Understanding HGF/MET's role is crucial for overcoming therapeutic resistance.
  • Targeting HGF/MET signaling may represent a strategy to improve the efficacy of cancer treatments.
Keywords:
EMTHGFMETdrug resistancetargeted therapies

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

6.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.4K